News & Resources

Corporate Profile

<< Back

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged release). Orexigen is undertaking a range of commercialization activities, both on their own and with key strategic partners to bring Contrave / Mysimba patients around the world.